47 results on '"Gladman, Dafna D"'
Search Results
2. Use of Apremilast to Achieve Psoriatic Arthritis Treatment Goals and Satisfaction at 1 Year in the Canadian Real-World APPRAISE Study
3. Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis
4. Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study
5. Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis
6. Investigation into the wait time for consultation in the psoriatic arthritis program
7. The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial
8. The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial
9. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021
10. Exploring cannabis use and perspectives among psoriatic disease patients
11. Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
12. Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial
13. Articular and Extra-Articular Benefits in ACR20 Non-responders at Week 104 Treated With Apremilast: Pooled Analysis of Three Randomized Controlled Trials
14. Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1
15. Secukinumab Efficacy on Psoriatic Arthritis GRAPPA-OMERACT Core Domains in Patients with or Without Prior Tumor Necrosis Factor Inhibitor Use: Pooled Analysis of Four Phase 3 Studies
16. Barriers to medication adherence and degree of nonadherence in a systemic lupus erythematosus (SLE) outpatient population
17. Author Correction: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021
18. The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus
19. Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib
20. Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
21. Axial Psoriatic Arthritis
22. Rho-GTPase pathways may differentiate treatment response to TNF-alpha and IL-17A inhibitors in psoriatic arthritis
23. Evolving concepts in systemic lupus erythematosus damage assessment
24. Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research
25. Correction to: The association between sonographic enthesitis and radiographic damage in psoriatic arthritis
26. Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis
27. Addressing comorbidities in psoriatic disease
28. Association of variably expressed KIR3dl1 alleles with psoriatic disease
29. Author Correction: Evolving concepts in systemic lupus erythematosus damage assessment
30. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysis
31. Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients
32. Comparison of systemic lupus erythematosus (SLE) patients managed early after diagnosis in specialty versus community care clinics
33. Psoriasis in systemic lupus erythematosus: a single-center experience
34. The association between sonographic enthesitis and radiographic damage in psoriatic arthritis
35. Widespread non-additive and interaction effects within HLA loci modulate the risk of autoimmune diseases
36. Correction to: Psoriasis in systemic lupus erythematosus: a single-center experience
37. Outcome Measures in Psoriatic Disease
38. Psoriatic Arthritis: Phenotypic Variance and Nosology
39. Review of Clinical Registries of Psoriatic Arthritis: Lessons Learned? Value for the Future?
40. Development of Screening Tools to Identify Psoriatic Arthritis
41. Update on Biomarkers in Psoriatic Arthritis
42. Epidemiology of atherosclerosis in systemic lupus erythematosus
43. The SLICC inception cohort for atherosclerosis
44. Axial disease in psoriatic arthritis
45. Traditional and Newer Therapeutic Options for Psoriatic Arthritis: An Evidence-Based Review
46. Can we identify psoriatic arthritis early?
47. Psoriatic Arthritis: Recognition and Management
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.